Qayyim Said
Research Subjects
Qayyim Said has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Bradley C. Martin
Division of Pharmaceutical Evaluation and Policy
2 shared publications- Amy M. Franks
Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
1 shared publication - Carrie McAdam-Marx
University of Utah, Pharmacotherapy Outcomes Research Center, Salt Lake City, UT, USA
1 shared publication Charles Kreilick
Bayer Healthcare Pharmaceuticals Wayne, NJUSA
1 shared publicationChenghui Li
Division of Pharmaceutical Evaluation and Policy
1 shared publication- Dean Blevins
University of Arkansas for Medical Sciences, Psychiatric Research Institute, 4301 W Markham St, #554, Little Rock, AR, 72205, USA
1 shared publication
Latest Publications
- 28 June 2012
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 32 (9) , 809-818
Effect of the Clopidogrel–Proton Pump Inhibitor Drug Interaction on Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome
Study Objective: To examine the effect of the drug interaction between clopidogrel and proton pump inhibitors (PPIs) on the risk of an adverse cardiovascular event.Design: Population‐based, retrospective cohort study.Data Source: IMS LifeLink Health Plan administrative claims database.Patients: A total of 10,101 patients aged 18 years or older with a diagnosis of acute coronary syndrome (ACS) made during a hospitalization or emergency department visit between 2001 and 2008 and who had their first clopidogrel prescription within 90 days after their ACS diagnosis were included in the study. Patients were stratified according to concurrent use (clopidogrel plus PPI group) or no use (clopidogrel alone group) of the following PPIs: esomeprazole, lansoprazole, omeprazole, pantoprazole, or rabeprazole.Measurements and Main Results: Data were collected on baseline patient demographic and clinical characteristics. Patients were followed from their first clopidogrel prescription until they experienced an adverse cardiovascular event, defined as inpatient hospitalization or emergency department visits for myocardial infarction, percutaneous coronary intervention, or intermediate coronary syndrome; were disenrolled; discontinued clopidogrel; or reached the end of the study period. Using a propensity scoring method, the clopidogrel plus PPI group was matched in a 1:1 ratio with the clopidogrel alone group. Exposure to overlapping clopidogrel‐PPI prescriptions was modeled as a time‐dependent covariate. The Cox hazards regression model was used to estimate the risk of an adverse cardiovascular event in the clopidogrel plus PPI group versus the clopidogrel alone group. Propensity score matching resulted in 2674 patient pairs. In the propensity score–matched sample, the mean age was 61.30 years, with a mean follow‐up of 268 days, and 70.04% were male. Concurrent use of clopidogrel with a PPI was associated with a significantly increased risk of a cardiovascular adverse event (hazard ratio 1.438, 95% confidence interval 1.237–1.671) compared with clopidogrel alone.Conclusion: Concurrent use of clopidogrel plus a PPI was associated with a significant increase in risk of an adverse cardiovascular event in patients with ACS. Large randomized studies are needed to confirm this finding. Until then, clinicians should prescribe the concurrent use of these two drugs cautiously.
- 28 June 2012
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 32 (9) , 809-818
Effect of the Clopidogrel–Proton Pump Inhibitor Drug Interaction on Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome
Study Objective: To examine the effect of the drug interaction between clopidogrel and proton pump inhibitors (PPIs) on the risk of an adverse cardiovascular event.Design: Population‐based, retrospective cohort study.Data Source: IMS LifeLink Health Plan administrative claims database.Patients: A total of 10,101 patients aged 18 years or older with a diagnosis of acute coronary syndrome (ACS) made during a hospitalization or emergency department visit between 2001 and 2008 and who had their first clopidogrel prescription within 90 days after their ACS diagnosis were included in the study. Patients were stratified according to concurrent use (clopidogrel plus PPI group) or no use (clopidogrel alone group) of the following PPIs: esomeprazole, lansoprazole, omeprazole, pantoprazole, or rabeprazole.Measurements and Main Results: Data were collected on baseline patient demographic and clinical characteristics. Patients were followed from their first clopidogrel prescription until they experienced an adverse cardiovascular event, defined as inpatient hospitalization or emergency department visits for myocardial infarction, percutaneous coronary intervention, or intermediate coronary syndrome; were disenrolled; discontinued clopidogrel; or reached the end of the study period. Using a propensity scoring method, the clopidogrel plus PPI group was matched in a 1:1 ratio with the clopidogrel alone group. Exposure to overlapping clopidogrel‐PPI prescriptions was modeled as a time‐dependent covariate. The Cox hazards regression model was used to estimate the risk of an adverse cardiovascular event in the clopidogrel plus PPI group versus the clopidogrel alone group. Propensity score matching resulted in 2674 patient pairs. In the propensity score–matched sample, the mean age was 61.30 years, with a mean follow‐up of 268 days, and 70.04% were male. Concurrent use of clopidogrel with a PPI was associated with a significantly increased risk of a cardiovascular adverse event (hazard ratio 1.438, 95% confidence interval 1.237–1.671) compared with clopidogrel alone.Conclusion: Concurrent use of clopidogrel plus a PPI was associated with a significant increase in risk of an adverse cardiovascular event in patients with ACS. Large randomized studies are needed to confirm this finding. Until then, clinicians should prescribe the concurrent use of these two drugs cautiously.
- 13 January 2012
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 15 (3) , 500-508
The cost to managed care of managing pulmonary hypertension
Objective: To estimate direct medical costs and resource use for commercially-insured patients within two pulmonary hypertension sub-groups: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Research design and methods: Using a retrospective cohort design, subjects (≥18 years) with ICD-9 code 416.0 (PAH or CTEPH) or 416.8 (CTEPH) were identified during 2004–2009 within the MarketScan database. The date of the first observed claim was the index date. Each PAH and CTEPH patient was matched to one-to-five controls without PAH and CTEPH on age, gender, region, and payer type. Patients and controls were continuously enrolled for at least 12 months pre- and 12 months post-index date. Per-patient-per-month costs and resource use were compared using Wilcoxon rank-sum test. Results: PAH patients (1647) and controls (6352) were identified (mean age 63 years, 73% female). Total monthly costs before PAH diagnosis were: PAH patients $2064 vs controls $1094. After PAH diagnosis, PAH patients had significantly higher monthly costs and resource use vs controls: Total costs $4021 vs $1533, outpatient visits 1.1 vs 0.8, inpatient visits 0.7 vs 0.2, prescriptions 3.6 vs 2.7, all p-values p-values Key limitations: Identification of PAH is complicated, as there exists no precise ICD-9-CM code for the condition. CTEPH diagnosis was based upon claims data and was not verified clinically. Conclusions: CTEPH and PAH patients incurred higher costs and used more resources than controls in the baseline and follow-up periods.
- 13 January 2012
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 15 (3) , 500-508
The cost to managed care of managing pulmonary hypertension
Objective: To estimate direct medical costs and resource use for commercially-insured patients within two pulmonary hypertension sub-groups: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Research design and methods: Using a retrospective cohort design, subjects (≥18 years) with ICD-9 code 416.0 (PAH or CTEPH) or 416.8 (CTEPH) were identified during 2004–2009 within the MarketScan database. The date of the first observed claim was the index date. Each PAH and CTEPH patient was matched to one-to-five controls without PAH and CTEPH on age, gender, region, and payer type. Patients and controls were continuously enrolled for at least 12 months pre- and 12 months post-index date. Per-patient-per-month costs and resource use were compared using Wilcoxon rank-sum test. Results: PAH patients (1647) and controls (6352) were identified (mean age 63 years, 73% female). Total monthly costs before PAH diagnosis were: PAH patients $2064 vs controls $1094. After PAH diagnosis, PAH patients had significantly higher monthly costs and resource use vs controls: Total costs $4021 vs $1533, outpatient visits 1.1 vs 0.8, inpatient visits 0.7 vs 0.2, prescriptions 3.6 vs 2.7, all p-values p-values Key limitations: Identification of PAH is complicated, as there exists no precise ICD-9-CM code for the condition. CTEPH diagnosis was based upon claims data and was not verified clinically. Conclusions: CTEPH and PAH patients incurred higher costs and used more resources than controls in the baseline and follow-up periods.
- Open Access
- 13 October 2010
- Published by Springer Nature in Implementation Science
- Vol. 5 (1) , 75
Employing external facilitation to implement cognitive behavioral therapy in VA clinics: a pilot study
Although for more than a decade healthcare systems have attempted to provide evidence-based mental health treatments, the availability and use of psychotherapies remains low. A significant need exists to identify simple but effective implementation strategies to adopt complex practices within complex systems of care. Emerging evidence suggests that facilitation may be an effective integrative implementation strategy for adoption of complex practices. The current pilot examined the use of external facilitation for adoption of cognitive behavioral therapy (CBT) in 20 Department of Veteran Affairs (VA) clinics.
- 13 October 2010
- Published by Springer Nature in Implementation Science
- Vol. 5 (1) , 75
Open AccessEmploying external facilitation to implement cognitive behavioral therapy in VA clinics: a pilot study
Although for more than a decade healthcare systems have attempted to provide evidence-based mental health treatments, the availability and use of psychotherapies remains low. A significant need exists to identify simple but effective implementation strategies to adopt complex practices within complex systems of care. Emerging evidence suggests that facilitation may be an effective integrative implementation strategy for adoption of complex practices. The current pilot examined the use of external facilitation for adoption of cognitive behavioral therapy (CBT) in 20 Department of Veteran Affairs (VA) clinics.
- Open Access
- 1 October 2008
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care Pharmacy
- Vol. 14 (8) , 756-767
Association Between Cardiometabolic Risk Factors and Body Mass Index Based on Diagnosis and Treatment Codes in an Electronic Medical Record Database
BACKGROUND: Managed care organizations (MCOs) have access to treatment and diagnosis information from administrative claims data but generally have limited or no access to clinical information about laboratory values or biometric values such as body mass index (BMI) or waist circumference. Thus, MCOs are generally unable to identify overweight patients with cardiometabolic risk factors that put them at a high risk of poor outcomes. The National Heart, Lung, and Blood Institute defines normal body weight as a BMI (ratio of weight in kilograms to height in meters squared [kg/m2]) from 18.5 to 24.9 kg/m2, overweight as 25.0 to 29.9 kg/m2, and obesity as a BMI of 30 kg/m2 or greater. Current guidelines for weight-loss pharmacotherapy, including U.S. Food and Drug Administration-approved label indications, specify use in patients with a BMI of 30 kg/m2 or greater, or a BMI greater than 27 kg/m2 and at least 1 concomitant cardiometabolic risk factor such as controlled hypertension, diabetes, or dyslipidemia. OBJECTIVE: To evaluate the association of cardiometabolic risk factors with BMI as recorded in a database of electronic medical records (EMRs). METHODS: Each patient had a minimum look-back observation period of 2 years from the last date of activity in the EMR. Patients with a BMI of 18 kg/m2 or greater recorded in the EMR at any time during the 10-year period from January 1996 through December 2005 were stratified into groups by the number of cardiometabolic risk factors and by individual cardiometabolic risk for those with just 1 risk factor. Cardiometabolic risk factors were identified from diagnoses and prescription orders in the EMR associated with high triglyceride levels, low high-density lipoprotein cholesterol (HDL-C) levels, type 2 diabetes, or hypertension. Unadjusted and adjusted odds ratios (ORs) of having a BMI greater than27 kg/m2 were calculated for each risk factor group and for patients with no risk factors. Using logistic regression analysis, ORs were adjusted for age, gender, insurance type, region, medications associated with weight gain or weight loss, and diseases that modify weight. RESULTS: A total of 499,593 patients with a BMI of 18 kg/m2 or greater were identified; 56.4% (n = 281,988) had a BMI greater than 27 kg/m2, whereas 43.6% (n = 217,605) had a BMI between 18 and 27 kg/m2. Compared with patients with no risk factors (n = 289,960), patients with 1-4 risk factors (n = 209,633) were significantly more likely to have a BMI greater than 27 kg/m2; 48.4% of patients without cardiometabolic risk factors had a BMI greater than 27 kg/m2, compared with 63.3%, 79.8%, 84.6%, and 88.5% for patients with 1-4 cardiometabolic risk factors, respectively (all comparisons P less than 0.001). Adjusted ORs for having a BMI greater than 27 kg/m2 were 2.64 (95% confidence interval [CI] = 2.51-2.77) for type 2 diabetes, 2.21 (95% CI = 2.05-2.37) for elevated triglycerides, 1.91 (95% CI = 1.88-1.94) for hypertension, and 1.45 (95% CI = 1.29-1.63) for low HDL-C. Adjusted ORs for having a BMI greater than 27 kg/m2 were 3.58 (95% CI = 3.47-3.69), 4.24 (95% CI = 3.93-4.59), and 5.07 (95% CI = 3.77-6.81) for patients with any 2, 3, and 4 risk factors respectively, relative to patients with no cardiometabolic risk factors. CONCLUSIONS: For patients with cardiometabolic risk factors, compared with patients with no risk factors, the odds of having a BMI greater than 27 kg/m2 were multiplied by 1.45-5.07, depending on the type and number of risk factors. Diagnoses and treatment indicators for cardiometabolic risk factors are potential indicators of obesity.
- 1 October 2008
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care Pharmacy
- Vol. 14 (8) , 756-767
Open AccessAssociation Between Cardiometabolic Risk Factors and Body Mass Index Based on Diagnosis and Treatment Codes in an Electronic Medical Record Database
BACKGROUND: Managed care organizations (MCOs) have access to treatment and diagnosis information from administrative claims data but generally have limited or no access to clinical information about laboratory values or biometric values such as body mass index (BMI) or waist circumference. Thus, MCOs are generally unable to identify overweight patients with cardiometabolic risk factors that put them at a high risk of poor outcomes. The National Heart, Lung, and Blood Institute defines normal body weight as a BMI (ratio of weight in kilograms to height in meters squared [kg/m2]) from 18.5 to 24.9 kg/m2, overweight as 25.0 to 29.9 kg/m2, and obesity as a BMI of 30 kg/m2 or greater. Current guidelines for weight-loss pharmacotherapy, including U.S. Food and Drug Administration-approved label indications, specify use in patients with a BMI of 30 kg/m2 or greater, or a BMI greater than 27 kg/m2 and at least 1 concomitant cardiometabolic risk factor such as controlled hypertension, diabetes, or dyslipidemia. OBJECTIVE: To evaluate the association of cardiometabolic risk factors with BMI as recorded in a database of electronic medical records (EMRs). METHODS: Each patient had a minimum look-back observation period of 2 years from the last date of activity in the EMR. Patients with a BMI of 18 kg/m2 or greater recorded in the EMR at any time during the 10-year period from January 1996 through December 2005 were stratified into groups by the number of cardiometabolic risk factors and by individual cardiometabolic risk for those with just 1 risk factor. Cardiometabolic risk factors were identified from diagnoses and prescription orders in the EMR associated with high triglyceride levels, low high-density lipoprotein cholesterol (HDL-C) levels, type 2 diabetes, or hypertension. Unadjusted and adjusted odds ratios (ORs) of having a BMI greater than27 kg/m2 were calculated for each risk factor group and for patients with no risk factors. Using logistic regression analysis, ORs were adjusted for age, gender, insurance type, region, medications associated with weight gain or weight loss, and diseases that modify weight. RESULTS: A total of 499,593 patients with a BMI of 18 kg/m2 or greater were identified; 56.4% (n = 281,988) had a BMI greater than 27 kg/m2, whereas 43.6% (n = 217,605) had a BMI between 18 and 27 kg/m2. Compared with patients with no risk factors (n = 289,960), patients with 1-4 risk factors (n = 209,633) were significantly more likely to have a BMI greater than 27 kg/m2; 48.4% of patients without cardiometabolic risk factors had a BMI greater than 27 kg/m2, compared with 63.3%, 79.8%, 84.6%, and 88.5% for patients with 1-4 cardiometabolic risk factors, respectively (all comparisons P less than 0.001). Adjusted ORs for having a BMI greater than 27 kg/m2 were 2.64 (95% confidence interval [CI] = 2.51-2.77) for type 2 diabetes, 2.21 (95% CI = 2.05-2.37) for elevated triglycerides, 1.91 (95% CI = 1.88-1.94) for hypertension, and 1.45 (95% CI = 1.29-1.63) for low HDL-C. Adjusted ORs for having a BMI greater than 27 kg/m2 were 3.58 (95% CI = 3.47-3.69), 4.24 (95% CI = 3.93-4.59), and 5.07 (95% CI = 3.77-6.81) for patients with any 2, 3, and 4 risk factors respectively, relative to patients with no cardiometabolic risk factors. CONCLUSIONS: For patients with cardiometabolic risk factors, compared with patients with no risk factors, the odds of having a BMI greater than 27 kg/m2 were multiplied by 1.45-5.07, depending on the type and number of risk factors. Diagnoses and treatment indicators for cardiometabolic risk factors are potential indicators of obesity.
- 26 March 2008
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 17 (4) , 354-364
Somnolence effects of antipsychotic medications and the risk of unintentional injury
Purpose This study examined the relationship between antipsychotic medications, categorized by published somnolence effects, and unintentional injury (UI). Methods The study population included patients of 18–64 years of age in a healthcare insurance database with claims from 2001 to 2004 and diagnoses of schizophrenia or affective disorder. A nested case-control design was used with cases defined by an E-code claim (a specified external cause of injury) for selected UIs. For cases, the index date referred to the first injury. For controls, the “control index date” was the date of claim if there was only a single medical claim; for patients with ≥2 claims, one was selected at random as the “control index date.” Both groups had a prescription for a first-generation antipsychotic (FGA) or second-generation antipsychotic (SGA) overlapping the index date. Potential somnolence effects were defined as: low (referent) – aripiprazole/ziprasidone; medium – risperidone; high – olanzapine/quetiapine: or any single FGA. Logistic regression models were used to estimate odds ratio (OR) and 95% confidence interval (CI) for UI, adjusted for gender, age, concomitant drug, and psychiatric diagnosis. Results Among 648 cases and 5214 controls, high-somnolence SGAs were associated with an OR of 1.41 95%CI (1.03–1.93) for risk of UI, while medium-somnolence SGAs, and FGAs had ORs of 1.17 95%CI (0.83–1.64) and 1.17 95%CI (0.79–1.74), respectively. When quetiapine and olanzapine were disaggregated, ORs were 1.61 95%CI (1.15–2.25) and 1.25 95%CI (0.89–1.74), respectively. Conclusions High-somnolence SGAs may lead to UI among patients. When prescribing antipsychotics, clinicians should consider potential somnolence. Copyright © 2008 John Wiley & Sons, Ltd.
- 26 March 2008
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 17 (4) , 354-364
Somnolence effects of antipsychotic medications and the risk of unintentional injury
Purpose This study examined the relationship between antipsychotic medications, categorized by published somnolence effects, and unintentional injury (UI). Methods The study population included patients of 18–64 years of age in a healthcare insurance database with claims from 2001 to 2004 and diagnoses of schizophrenia or affective disorder. A nested case-control design was used with cases defined by an E-code claim (a specified external cause of injury) for selected UIs. For cases, the index date referred to the first injury. For controls, the “control index date” was the date of claim if there was only a single medical claim; for patients with ≥2 claims, one was selected at random as the “control index date.” Both groups had a prescription for a first-generation antipsychotic (FGA) or second-generation antipsychotic (SGA) overlapping the index date. Potential somnolence effects were defined as: low (referent) – aripiprazole/ziprasidone; medium – risperidone; high – olanzapine/quetiapine: or any single FGA. Logistic regression models were used to estimate odds ratio (OR) and 95% confidence interval (CI) for UI, adjusted for gender, age, concomitant drug, and psychiatric diagnosis. Results Among 648 cases and 5214 controls, high-somnolence SGAs were associated with an OR of 1.41 95%CI (1.03–1.93) for risk of UI, while medium-somnolence SGAs, and FGAs had ORs of 1.17 95%CI (0.83–1.64) and 1.17 95%CI (0.79–1.74), respectively. When quetiapine and olanzapine were disaggregated, ORs were 1.61 95%CI (1.15–2.25) and 1.25 95%CI (0.89–1.74), respectively. Conclusions High-somnolence SGAs may lead to UI among patients. When prescribing antipsychotics, clinicians should consider potential somnolence. Copyright © 2008 John Wiley & Sons, Ltd.